S evertheless, the anti-restenotic mechanism of action of E 2 is not fully understood and ontroversial results regarding its effects on vascular remodelling have been reported [5] [6] [7] [8] .
his phenomenon may be attributed to the presence of two distinct estrogen receptors (ERs) the vasculature, ER and ER . ERs are ligand-activated transcription factors [9] and and ER are highly homologous, activation of either one of them may lead to activities [10] [11] [12] [13] . So far, studies in ER knockout mice ent of ER in the protective effect of E 2 on theless, the role of ER in mediating the anti-restenotic properties of ER than to ER [18] , whereas the 2,3-bis(4-hydroxy-phenyl)-propionitrile (DPN) binds to at the non-constrictive perivascular cuff to induce neointima formation can be injury-induced neointima formation.
.1. Local delivery of E 2 using E 2 -eluting cuffs
E
ER with an 72-fold higher affinity compared to ER [19] . Therefore, these compounds provide an attractive pharmacological approach to elucidate the biological role of ER on neointima formation.
A well-defined mouse model of neointima formation consists of placement of a nonconstrictive perivascular cuff around the mouse femoral artery [20, 21] . Previously, we showed th constructed from a polymeric formulation suitable for controlled drug delivery. This novel drug-eluting cuff simultaneously induces reproducible neointima formation and allows locally confined delivery of drugs to the cuffed vessel segment [22] [23] [24] [25] .
In the present study, we assessed the respective role of vascular ER and ER in the anti-restenotic properties of E 2 in a mouse model of restenosis. By local delivery of PPT, an ER -selective agonist, and DPN, a selective ER agonist, we demonstrated that in addition to ER , ER activation leads to neointima formation inhibition in a murine model. These data reveal a yet unidentified protective role of ER in
RESULTS

3
in vitro release profiles
In vitro release profiles of drug-eluting cuffs loaded with 1% and 5% (w/w) E 2 was determined for a three weeks period. E 2 was released in a dose-dependent manner over the 21-day period for both concentrations used (1%: 30.9±14 g; 5%: 211±14 g).
Effect of perivascular delivery of E 2 on neointima formation
To assess the effect of local perivascular E 2 delivery on cuff-induced neointima formation, drug-eluting cuffs were loaded with 1% and 5% E 2 and placed around the femoral artery of male C57BL/6 mice for a 21-day period. Microscopic analysis of the cuffed femoral artery (Fig. 1A) . Morphometric ima formation between mice n E 2 -eluting cuff (Fig. 1B) . 
Local specific activation of ER and ER in femoral arteries
PPT and DPN in vitro release profiles
To examine whether PPT and DPN were suitably loaded and released from our drug delivery device, the in vitro release profiles of 0.5%, 1%, 2.5% and 5% PPT-and 1% and 5% DPN-eluting cuffs were assessed. PPT showed a sustained and dose-dependent release for the 21-day period (0.5%: 16±0.4 g; 1%: 36±2 g; 2.5%: 68±1 g; 5%: 160±6 g). DPN was also released from the drug-eluting cuffs in a dose-dependent manner over time. In total, 33±1 g was released from the 1% and 83±3 g from the 5% DPN-eluting cuffs, respectively.
Effect of PPT-and DPN-selective ER subtypes activation on neointima formation
To assess the role of ER in the E 2 -mediated inhibition of cuff-induced neointima formation, drug-eluting cuffs were loaded with 0.5%, 1%, 2.5%, and 5% PPT, a highly specific ER ligand, and placed around the femoral artery of mice for three weeks. It should be noted that a broader concentration range of PPT was used as compared to E 2 and DPN.
This was due to the seemingly contrasting data observed with the 1% and 5% PPT-eluting cuffs on neointima formation, as discussed below.
In animals receiving a control drug-eluting cuff a neointima had been formed.
Remarkably, morphometric quantification revealed only a significant inhibition of cuffinduced neointima formation in the cuffed segments treated with the lowest PPT concentrations. Cuffed arteries locally treated with higher PPT concentrations (2.5 and 5%)
did not show an inhibitory effect on neointima formation as compared with control cuffed arteries ( Fig. 3A and 3C By placing a 1% and 5% (w/w) DPN-eluting cuff around the femoral artery of male 57BL/6 mice for 21 days, the role of ER on neointima formation was assessed orphometric analysis of the cuffed arteries of both DPN-treated groups showed a significan hibition of neointima formation as compared to control cuffed segments ( Fig. 3B and 3D) oreover, intima/media ratios of the DPN-treat PPT-or (D) DPN-eluting cuff placement. Total intimal area was quantified by image analysis using ten sections in each cuffed artery and expressed in m 2 (mean SEM, n=6). NS, P>0.05 (NS, not significant); *P<0.05; **P<0.01. E: Percentage of BrdU-positive cells in cuffed femoral arteries treated with increasing concentrations of PPT (0.5 and 2.5%) and DPN (1 and 5%) 21 days after drug-eluting cuff placement. BrdU-labeled nuclei were counted in six equally spaced cross-sections from each cuffed artery and expressed as a percentage of the total number of nuclei. Mean SEM, n=6. NS, P>0.05 (NS, not significant); *P<0.05.
To further investigate the apparent discrepancy on cuff-induced neointima formation between animals perivascularly treated with either an ER or an ER specific agonist, DNA synthesis was evaluated. Cellular proliferation was assessed by examining incorporation of 5-bromo-2'-deoxyuridine (BrdU) into DNA at 21 days after cuff placement in mice receiving either a control drug-eluting cuff, a PPT-(0.5% and 5%) or a DPN-eluting cuff (1% and 5%).
As depicted in Fig. 3E , a profound incorporation of BrdU was observed 21 days after surgery in cuffed vessel segments receiving a control drug-eluting cuff (3.45±0.25%). In line with the morphometric analysis, only the 0.5% PPT-eluting cuff showed a decreased cellular proliferation but not the higher PPT dosage (0.5%: 1.62±0.43%, P=0.02; 2.5%: 2.95±1.01%,
P=0.18).
Conversely, cuffed artery segments of mice receiving either a 1% or a 5% DPNeluting cuff showed a significantly decreased cellular proliferation as compared to control cuffed arteries (1%: 1.71±0.50%, P=0.016; 5%: 1.27±0.43%, P=0.016).
DISCUSSION
The present study evaluates the respective roles of vascular ER and ER on neointima formation. Here we show, for the first time, the effects of specific ER subtype ligands on cuff-induced neointima formation in the mouse femoral artery. Local E 2 treatment resulted in a substantial and significant inhibition of cuff-induced neointima formation (Fig.   1) . Surprisingly, mice receiving the PPT-eluting cuffs displayed a significant reduction on neointima formation only for the lower PPT concentrations (0.5%: 78 3%; 1%: 56 8%) but not for the 2.5% and 5% PPT-eluting cuffs. Conversely, perivascular delivery of DPN displayed an inhibitory effect on cuff-induced neointima formation at both low and high concentrations (1%: 50 10%; 5%: 67 7%) (Fig. 3 ). E 2 has been shown to have vasoprotective properties. In rats, systemic E 2 therapy resulted in reduced vascular SMC proliferation and migration, which are fundamental steps in restenosis development [5] . In porcine coronary arteries, it has been shown that local delivery of E 2 decreases post-angioplasty restenosis due to endothelial function improvement [26] [27] [28] . resent study we demonstrate that both ER subtypes are expressed in cuffed femoral arteries Furthermore, the first short-term human pilot study using E 2 -eluting stents showed low rates f restenosis [29] . E o 2 mediates its effects primarily via interaction with its receptors ER and/or ER . ecently, we have generated a drug-eluting polymer cuff which enables local delivery of ompounds to the vasculature in an established mouse model of restenosis [22] [23] [24] [25] . In the (Fig 2) . Therefore, both ER subtypes may be accountable for the inhibitory effect of E 2 on cuff-induced neointima formation.
Thus far, the specific role of vascular ER subtypes in the vascular wall is not fully elucidated. The current knowledge of the respective role of vascular ER subtypes derives almost exclusively from ER -and ER -null mouse models [14] [15] [16] [17] . Although ER-null mice provide interesting clues, they imply several shortcomings. Due to whole body ER deficiency, direct vascular effects of E 2 cannot be discriminated from systemic effects. In addition, potential compensatory mechanisms may have occurred during development. In the past, Pare and colleagues [17] have demonstrated very elegantly that in ER -null mice E 2 does not have a protective effect on injury-induced vascular remodelling. However, although the concentration of E 2 used in these studies are optimal for activating ER (mean circulating levels of 0.33 to 0.43 nmol/L) it might be suboptimal on activating the E n To dissec ER nd ER -selective agonists, PPT and DPN, were used. The selectivity of PPT and DPN for both receptor subtypes enables detailed analysis of the contribution of both ERs to the protective effects on neointima formation in the current experiments. PPT induces exclusively ER mediated transcription and not ER (Kd for ER =0.4 nM and for ER =417 nM) [18] .
Thus, PPT can be stated as a highly selective ER agonist. In vivo, we demonstrated that local release of PPT led to either anti-restenotic effects or no effect on restenosis, as low dosages inhibited neointima formation whereas high concentrations did not.
On the other hand, DPN displays ER specificity (Kd for ER =80 nM and for ER =2.8 nM) [19] . Also in vivo DPN seems to act li ic administration of the relatively high dose of 1 mg/kg/day DPN to rats does not alter uterine weight, which is regarded as a true ER target tissue [30] . In the present study, both low and high concentrations of DPN led to an inhibition of neointima formation. Therefore we can state that, in this model, activation of ER seems to have a protective effect on injuryinduced neointima formation.
The surprisi neointima formation at higher dosages suggests a so called bell-shaped response curve, often seen when nuclear receptors are activated, might occur also in case of PPTmediated activation of ER . However, since E 2 activation does not show this response curve in our present studies and the Kd for the ER for E and PPT are similar (0.2 and 0.4 nM, 2 respectively) we do not believe this is the explanation for the observed phenomenon.
Currently, the reason for the observed response curve for PPT is not fully understood.
son Ltd. (Bristol, UK). Poly( -caprolactone)-based drug delivery cuffs w described elsewhere [22] . Calibration graphs of the different compounds were established by measuring the absorbance of a set of standards of each compound in the 0-50 g/ml ritoneal injection of 5 mg/kg Dormicum (Roche, Basel,
Switze
In conclusion, while literature proposes ER as the major receptor involved in the anti-restenotic and anti-atherosclerotic effects of E 2 . Our data provide evidence for a yet unidentified protective role of ER in injury-induced neointima formation as well.
Nevertheless, there seem to be complex and dose-dependent opposite roles for ER and ER in vascular tissue.
METHODS
Drug-eluting cuffs and in vitro release profiles
E 2 was purchased from Sigma Diagnostics (St Louis, USA). PPT and DPN were obtained from Tocris Cook ere manufactured as previously described [22] . Drug-loaded cuffs were made from the different blended molten drug-polymer mixtures and designed to fit around the femoral artery of mice. Drug-eluting cuffs had the shape of a longitudinal cut cylinder with an internal diameter of 0.5 mm, an external diameter of 1.0 mm, a length of 2.0 mm and a weight of approximately 5.0 mg.
Drug-eluting cuffs were loaded with 1% and 5% (w/w) E 2 , with 1% and 5% (w/w) DPN and with 0.5%, 1%, 2.5%, and 5% (w/w) PPT. In vitro release profiles (n=5/group) were performed by UV-VIS absorbance methods (225nm, 235nm and 257nm, respectively) as concentration range.
Femoral artery cuff mouse model
For experiments, 10-12 weeks old male C57BL/6 mice were used. Animals were fed a standard chow diet (R/M-H, Ssniff, Soest, Germany). At the time of surgery, mice were anaesthetized with an intrape rland), 0.5 mg/kg Dormitor (Orion, Helsinki, Finland) and 0.05 mg/kg Fentanyl (Janssen, Geel, Belgium). The femoral artery was dissected from its surroundings and loosely sheathed with a non-constrictive cuff [21, 22] . Either a control empty cuff, an E 2 -eluting cuff (1% and 5% w/w), a PPT-eluting cuff (0.5%, 1%, 2.5%, and 5% w/w), or a DPN-eluting cuff (1% and 5% w/w) was used (n=6/group).
All animal work was approved by TNO institutional regulatory authority and carried out in compliance with guidelines issued by the Dutch government. The investigation conform re sacrificed 21 days after cuff placement. Histological analyses were erformed as described previously [21] [22] [23] . All samples were routinely stained with hloxine-saffron (HPS). Weigert´s elastin staining was used to visualize elastic minae. arteries. Data are presented as fold induction (normalized to T=0 days), which was ca t [25] .
Statistical analysis
Results are expressed as mean SEM. Data were analyzed using the Mann-Whitney U test (SPSS 11.5). A value of P<0.05 was considered statistically significant. 
